CATHY ENG

TitleProfessor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. LaPelusa M, Shen C, Gillaspie EA, Cann C, Lambright E, Chakravarthy AB, Gibson MK, Eng C. Variation in Treatment Patterns of Patients with Early-Onset Gastric Cancer. Cancers (Basel). 2022 Jul 26; 14(15). PMID: 35892891.
      Citations:    
    2. Goldberg RM, Adams R, Buyse M, Eng C, Grothey A, André T, Sobrero AF, Lichtman SM, Benson AB, Punt CJA, Maughan T, Burzykowski T, Sommeijer D, Saad ED, Shi Q, Coart E, Chibaudel B, Koopman M, Schmoll HJ, Yoshino T, Taieb J, Tebbutt NC, Zalcberg J, Tabernero J, Van Cutsem E, Matheson A, de Gramont A. Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. J Natl Cancer Inst. 2022 06 13; 114(6):819-828. PMID: 34865086.
      Citations:    Fields:    Translation:Humans
    3. Jácome AA, Morris VK, Eng C. The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies. Curr Treat Options Oncol. 2022 Aug; 23(8):1073-1085. PMID: 35666353.
      Citations:    Fields:    
    4. Eng C, Ciombor KK, Cho M, Dorth JA, Rajdev LN, Horowitz DP, Gollub MJ, Jácome AA, Lockney NA, Muldoon RL, Washington MK, O'Brian BA, Benny A, Lebeck Lee CM, Benson AB, Goodman KA, Morris VK. Anal Cancer: Emerging Standards in a Rare Rare Disease. J Clin Oncol. 2022 Jun 01; JCO2102566. PMID: 35649196.
      Citations:    Fields:    
    5. Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari A. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open. 2022 05 02; 5(5):e2213588. PMID: 35608860.
      Citations:    Fields:    Translation:Humans
    6. Lin D, El Alam MB, Jaoude JA, Kouzy R, Phan JL, Elnaggar JH, Resendiz B, Medrano AYD, Lynn EJ, Nguyen ND, Noticewala SS, Mathew GG, Holliday EB, Minsky BD, Das P, Morris VK, Eng C, Mezzari MP, Petrosino JF, Ajami NJ, Klopp AH, Taniguchi CM, Colbert LE. Microbiome Dynamics During Chemoradiation Therapy for Anal Cancer. Int J Radiat Oncol Biol Phys. 2022 Aug 01; 113(5):974-984. PMID: 35513187.
      Citations:    Fields:    Translation:Humans
    7. Eng C, Holowatyj AN. Colorectal Cancer Genomics by Genetic Ancestry. Cancer Discov. 2022 05 02; 12(5):1187-1188. PMID: 35491647.
      Citations:    Fields:    Translation:Humans
    8. Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol. 2022 Apr; 13(2):647-656. PMID: 35557581.
      Citations:    
    9. Lebeck Lee CM, Ziogas IA, Agarwal R, Alexopoulos SP, Ciombor KK, Matsuoka LK, Brown DB, Eng C. A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer. Cancer. 2022 06 15; 128(12):2243-2257. PMID: 35285949.
      Citations:    Fields:    Translation:Humans
    10. Peterson SK, Basen-Engquist K, Demark-Wahnefried W, Prokhorov AV, Shinn EH, Martch SL, Beadle BM, Garden AS, Farcas E, Brandon Gunn G, Fuller CD, Morrison WH, Rosenthal DI, Phan J, Eng C, Cinciripini PM, Karam-Hage MA, Camero Garcia M, Patrick K. Feasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention. AMIA Annu Symp Proc. 2021; 2021:979-988. PMID: 35308916.
      Citations:    Fields:    Translation:Humans
    11. Holliday EB, Morris VK, Johnson B, Eng C, Ludmir EB, Das P, Minsky BD, Taniguchi C, Smith GL, Koay EJ, Koong AC, Delclos ME, Skibber JM, Rodriguez-Bigas MA, You YN, Bednarski BK, Tillman MM, Chang GJ, Jennings K, Messick CA. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist. 2022 02 03; 27(1):40-47. PMID: 35305097.
      Citations:    Fields:    Translation:Humans
    12. Eng C, Jácome AA, Agarwal R, Hayat MH, Byndloss MX, Holowatyj AN, Bailey C, Lieu CH. A comprehensive framework for early-onset colorectal cancer research. Lancet Oncol. 2022 03; 23(3):e116-e128. PMID: 35090673.
      Citations: 2     Fields:    Translation:Humans
    13. Miranda KW, Cimino SK, Eng C. Targeted Fibroblast Growth Factor Receptor (FGFR) Inhibition in Recurrent, Metastatic Anal Carcinoma: A Case Report. Clin Colorectal Cancer. 2022 Jan 20. PMID: 35125320.
      Citations:    Fields:    
    14. LaPelusa M, Shen C, Arhin ND, Cardin D, Tan M, Idrees K, Geevarghese S, Chakravarthy B, Berlin J, Eng C. Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer. Cancers (Basel). 2022 Jan 07; 14(2). PMID: 35053447.
      Citations: 2     
    15. Tchelebi LT, Eng C, Messick CA, Hong TS, Ludmir EB, Kachnic LA, Zaorsky NG. Current treatment and future directions in the management of anal cancer. CA Cancer J Clin. 2022 03; 72(2):183-195. PMID: 34847242.
      Citations: 1     Fields:    Translation:Humans
    16. Lebeck Lee C, Zwerner J, O'Brian B, Eng C. Cutaneous Lymphangitic Carcinomatosis as the First Sign of Recurrent Malignancy in a Patient With a History of Rectal Adenocarcinoma. Clin Colorectal Cancer. 2021 12; 20(4):368-371. PMID: 34690067.
      Citations: 1     Fields:    Translation:Humans
    17. Holowatyj AN, Eng C, Lewis MA. Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer. JCO Oncol Pract. 2022 03; 18(3):169-172. PMID: 34554830.
      Citations: 1     Fields:    Translation:Humans
    18. Rogers JE, Woodard TL, Gonzalez GM, Dasari A, Johnson B, Morris VK, Kee B, Vilar E, Nancy You Y, Chang GJ, Bednarski B, Skibber JM, Rodriguez-Bigas MA, Eng C. Colorectal cancer during pregnancy or postpartum: Case series and literature review. Obstet Med. 2022 Jun; 15(2):118-124. PMID: 35845232.
      Citations:    
    19. Cardin DB, Eng C. Pancreatic Cancer in Young Adults: Can Innovative Approaches Lead to Better Outcomes? J Natl Cancer Inst. 2021 09 04; 113(9):1125-1126. PMID: 33755179.
      Citations:    Fields:    Translation:Humans
    20. Eng C, Hochster H. Early-Onset Colorectal Cancer: The Mystery Remains. J Natl Cancer Inst. 2021 Aug 18. PMID: 34405226.
      Citations:    Fields:    
    21. Arhin ND, Shen C, Bailey CE, Matsuoka LK, Hawkins AT, Holowatyj AN, Ciombor KK, Hopkins MB, Geiger TM, Kam AE, Roth MT, Lebeck Lee CM, Lapelusa M, Dasari A, Eng C. Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients. Cancer Med. 2021 07; 10(13):4269-4281. PMID: 34132476.
      Citations:    Fields:    Translation:Humans
    22. Hubbard JM, Eng C, Cremolini C, Marshall JL. Considerations in the management of younger patients With colorectal cancer: Q&A. Clin Adv Hematol Oncol. 2021 06; 19 Suppl 16(6):15-17. PMID: 35289792.
      Citations:    Fields:    Translation:Humans
    23. Eng C. Examining the increase in colorectal cancer in younger patients. Clin Adv Hematol Oncol. 2021 Jun; 19 Suppl 16(6):3-6. PMID: 35289788.
      Citations:    Fields:    Translation:Humans
    24. Hubbard JM, Eng C, Cremolini C, Marshall JL. Considerations in the management of younger patients with colorectal cancer. Clin Adv Hematol Oncol. 2021 Jun; 19 Suppl 16(6):1-20. PMID: 35289787.
      Citations:    Fields:    Translation:Humans
    25. Rogers JE, Woodard TL, Dasari A, Kee B, Das P, Bednarski BK, Skibber JM, Rodriguez-Bigas MA, Eng C. Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience. Support Care Cancer. 2021 Dec; 29(12):7351-7354. PMID: 34050401.
      Citations: 1     Fields:    Translation:Humans
    26. Hester R, Advani S, Rashid A, Holliday E, Messick C, Das P, You YN, Taniguchi C, Koay EJ, Bednarski B, Rodriguez-Bigas M, Skibber J, Wolff R, Chang GJ, Minsky BD, Foo WC, Rothschild N, Morris VK, Eng C. CEA as a blood-based biomarker in anal cancer. Oncotarget. 2021 May 25; 12(11):1037-1045. PMID: 34084278.
      Citations:    Fields:    
    27. Dasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, Chien C, Kania M, Tabernero J, Eng C. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncol. 2021 Aug; 17(24):3151-3162. PMID: 33993740.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    28. Livingston AJ, Bailey CE, Washington MK, Eng C. Squamous Cell Carcinoma of the Anal Verge with Sigmoid Colon Metastasis. Clin Colorectal Cancer. 2021 09; 20(3):e210-e213. PMID: 34092493.
      Citations:    Fields:    Translation:Humans
    29. Cohen AS, Grudzinski J, Smith GT, Peterson TE, Whisenant JG, Hickman TL, Ciombor KK, Cardin D, Eng C, Goff LW, Das S, Coffey RJ, Berlin JD, Manning HC. First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer. J Nucl Med. 2022 01; 63(1):36-43. PMID: 33931465.
      Citations: 3     Fields:    
    30. Cimino SK, Ciombor KK, Chakravarthy AB, Bailey CE, Hopkins MB, Geiger TM, Hawkins AT, Eng C. Safety considerations with new treatment regimens for anal cancer. Expert Opin Drug Saf. 2021 Aug; 20(8):889-902. PMID: 33900857.
      Citations: 2     Fields:    Translation:Humans
    31. Gibbs T, Washington MK, Eng C, Idrees K, Davis J, Holowatyj AN. Histologic and Racial/Ethnic Patterns of Appendiceal Cancer among Young Patients. Cancer Epidemiol Biomarkers Prev. 2021 06; 30(6):1149-1155. PMID: 33795212.
      Citations:    Fields:    Translation:Humans
    32. Kam AE, Eng C. BRAF V600E mutated metastatic colorectal cancer: current progress and future directions. Expert Opin Biol Ther. 2021 10; 21(10):1311-1313. PMID: 33761808.
      Citations:    Fields:    Translation:Humans
    33. Eng C, Chen EY, Rogers J, Lewis M, Strosberg J, Thota R, Krishnamurthi S, Oberstein P, Govindarajan R, Buchschacher G, Patel S, Sohal D, Al-Toubah T, Philip P, Dasari A, Kennecke H, Stein S. Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncol Pract. 2021 10; 17(10):607-614. PMID: 33534616.
      Citations: 4     Fields:    Translation:HumansCells
    34. Eng C. BRAF Mutation in Colorectal Cancer: An Enigmatic Target. J Clin Oncol. 2021 02 01; 39(4):259-261. PMID: 33503394.
      Citations: 2     Fields:    Translation:Humans
    35. Sobrero A, Lenz HJ, Eng C, Scheithauer W, Middleton G, Chen W, Esser R, Nippgen J, Burris H. Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. Oncologist. 2021 02; 26(2):e261-e269. PMID: 33191588.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    36. Holowatyj AN, Eng C, Wen W, Idrees K, Guo X. Spectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age at Disease Onset. JAMA Netw Open. 2020 12 01; 3(12):e2028644. PMID: 33295976.
      Citations: 4     Fields:    Translation:Humans
    37. Jácome AA, Vreeland TJ, Johnson B, Kawaguchi Y, Wei SH, Nancy You Y, Vilar E, Vauthey JN, Eng C. The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. Br J Cancer. 2021 02; 124(4):797-804. PMID: 33208919.
      Citations: 1     Fields:    Translation:Humans
    38. Rogers JE, Jácome AAA, Ohinata A, Wolff R, Morris VK, Johnson B, Mehdizadeh A, Rothschild ND, Ahmed SU, Guerra JL, Eng C. Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. Expert Rev Anticancer Ther. 2020 10; 20(10):901-908. PMID: 32799569.
      Citations: 1     Fields:    Translation:Humans
    39. Raghav K, Shen JP, Jácome AA, Guerra JL, Scally CP, Taggart MW, Foo WC, Matamoros A, Shaw KR, Fournier K, Overman MJ, Eng C. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer. 2020 10; 123(8):1262-1270. PMID: 32733093.
      Citations: 1     Fields:    Translation:Humans
    40. Noticewala SS, Ludmir EB, Eng C, Holliday EB, Minsky BD, Morris VK, Das P. Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al. Radiother Oncol. 2020 10; 151:56-57. PMID: 32710989.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    41. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020 08 20; 38(24):2782-2797. PMID: 32658626.
      Citations: 39     Fields:    Translation:Humans
    42. Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. Evolution of Cancer Care in Response to the COVID-19 Pandemic. Oncologist. 2020 09; 25(9):e1426-e1427. PMID: 32536024.
      Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
    43. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 12; 17(12):757-770. PMID: 32632268.
      Citations: 60     Fields:    Translation:Humans
    44. Demisse R, Damle N, Kim E, Gong J, Fakih M, Eng C, Oesterich L, McKenny M, Ji J, Liu J, Louie R, Tam K, Gholami S, Halabi W, Monjazeb A, Dayyani F, Cho M. Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. J Natl Compr Canc Netw. 2020 07; 18(7):798-804. PMID: 32634770.
      Citations: 10     Fields:    Translation:Humans
    45. Lou E, Beg MS, Bergsland E, Eng C, Khorana AA, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY. Reply to S. Boutayeb et al. JCO Oncol Pract. 2020 08; 16(8):525. PMID: 32574129.
      Citations: 1     Fields:    Translation:HumansCells
    46. Holowatyj AN, Washington KM, Salaria SN, Lieu CH, Idrees K, Eng C. Early-Onset Appendiceal Cancer Survival by Race or Ethnicity in the United States. Gastroenterology. 2020 10; 159(4):1605-1608. PMID: 32540351.
      Citations: 3     Fields:    Translation:Humans
    47. Jácome AA, Ohinata A, Mahvash A, Overman MJ, Kee B, Fogelman D, Morris VK, Johnson B, Rothschild ND, Wolff RA, Eng C. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer. 2020 12; 19(4):e189-e199. PMID: 32680816.
      Citations:    Fields:    Translation:Humans
    48. Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, Benson A, Bryant A, Peckitt C, Segelov E, Roy A, Seymour MT, Welch J, Saunders MP, Muirhead R, O'Dwyer P, Bridgewater J, Bhide S, Glynne-Jones R, Arnold D, Cunningham D. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol. 2020 08 01; 38(22):2510-2518. PMID: 32530769.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    49. Jácome AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng C. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6. PMID: 32665092.
      Citations:    Fields:    Translation:Humans
    50. Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. In Reply. Oncologist. 2020 08; 25(8):e1252-e1253. PMID: 32378772.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    51. Ajani JA, Javle M, Eng C, Fogelman D, Smith J, Anderson B, Zhang C, Iizuka K. Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs. 2020 12; 38(6):1763-1773. PMID: 32377978.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    52. Lou E, Beg S, Bergsland E, Eng C, Khorana A, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY. Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. JCO Oncol Pract. 2020 07; 16(7):383-388. PMID: 32352884.
      Citations: 11     Fields:    Translation:HumansCellsPHPublic Health
    53. Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Meyers BM, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. Oncologist. 2020 06; 25(6):e936-e945. PMID: 32243668.
      Citations: 262     Fields:    Translation:HumansCellsPHPublic Health
    54. Eng C, Fakih M, Amin M, Morris V, Hochster HS, Boland PM, Uronis H. A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget. 2020 Apr 14; 11(15):1334-1343. PMID: 32341753.
      Citations: 3     Fields:    
    55. Eng C. TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer? Lancet Oncol. 2020 03; 21(3):326-327. PMID: 31999945.
      Citations:    Fields:    Translation:Humans
    56. Yennurajalingam S, Carmack C, Balachandran D, Eng C, Lim B, Delgado M, Guzman Gutierrez D, Raznahan M, Park M, Hess KR, Williams JL, Lu Z, Ochoa J, Bruera E. Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. BMJ Support Palliat Care. 2021 Jun; 11(2):170-179. PMID: 31924662.
      Citations: 1     Fields:    Translation:Humans
    57. Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931. PMID: 31852833.
      Citations: 17     Fields:    Translation:Humans
    58. Jácome AA, Eng C. Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. Expert Opin Biol Ther. 2019 12; 19(12):1247-1263. PMID: 31642347.
      Citations: 17     Fields:    Translation:Humans
    59. Sánchez NS, Kahle MP, Bailey AM, Wathoo C, Balaji K, Demirhan ME, Yang D, Javle M, Kaseb A, Eng C, Subbiah V, Janku F, Raymond VM, Lanman RB, Mills Shaw KR, Meric-Bernstam F. Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precis Oncol. 2019; 3. PMID: 32923868.
      Citations: 3     Fields:    
    60. Rogers JE, Eng C. Pharmacotherapeutic considerations for elderly patients with colorectal cancer. Expert Opin Pharmacother. 2019 Dec; 20(17):2139-2160. PMID: 31456458.
      Citations: 1     Fields:    Translation:Humans
    61. Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510. PMID: 31406299.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    62. Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol. 2019; 3. PMID: 32914034.
      Citations: 4     Fields:    
    63. Johnson B, Eng C. More questions regarding HIPEC in colorectal carcinomatosis. Lancet Gastroenterol Hepatol. 2019 10; 4(10):744-745. PMID: 31371229.
      Citations: 2     Fields:    Translation:Humans
    64. Eng C, Jácome AA, Das P, Chang GJ, Rodriguez-Bigas M, Skibber JM, Wolff RA, Qiao W, Xing Y, Sethi S, Ohinata A, Crane CH. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. Clin Colorectal Cancer. 2019 12; 18(4):301-306. PMID: 31350201.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    65. Wang XS, Shi Q, Bhadkamkar NA, Cleeland CS, Garcia-Gonzalez A, Aguilar JR, Heijnen C, Eng C. Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. J Pain Symptom Manage. 2019 10; 58(4):662-671. PMID: 31254639.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    66. Lieu CH, Golemis EA, Serebriiskii IG, Newberg J, Hemmerich A, Connelly C, Messersmith WA, Eng C, Eckhardt SG, Frampton G, Cooke M, Meyer JE. Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. Clin Cancer Res. 2019 10 01; 25(19):5852-5858. PMID: 31243121.
      Citations: 37     Fields:    Translation:Humans
    67. Eng C, Messick C, Glynne-Jones R. The Management and Prevention of Anal Squamous Cell Carcinoma. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:216-225. PMID: 31099616.
      Citations: 1     Fields:    Translation:Humans
    68. Chun YS, Passot G, Yamashita S, Nusrat M, Katsonis P, Loree JM, Conrad C, Tzeng CD, Xiao L, Aloia TA, Eng C, Kopetz SE, Lichtarge O, Vauthey JN. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. Ann Surg. 2019 05; 269(5):917-923. PMID: 28767562.
      Citations: 52     Fields:    Translation:Humans
    69. Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 06; 20(6):849-861. PMID: 31003911.
      Citations: 128     Fields:    Translation:HumansCTClinical Trials
    70. Eng C, Rogers JE. Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. Expert Opin Pharmacother. 2019 Apr; 20(5):523-534. PMID: 30590946.
      Citations: 1     Fields:    Translation:Humans
    71. Jacome AA, Eng C. Experimental and investigational drugs for the treatment of anal cancer. Expert Opin Investig Drugs. 2018 12; 27(12):941-950. PMID: 30381968.
      Citations: 1     Fields:    Translation:Humans
    72. Jensen G, Tao R, Eng C, Skibber JM, Rodriguez-Bigas M, Chang GJ, You YN, Bednarski BK, Minsky BD, Koay E, Taniguchi C, Krishnan S, Das P. Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):595-600. PMID: 30370360.
      Citations: 1     
    73. Goumard C, Nancy You Y, Okuno M, Kutlu O, Chen HC, Simoneau E, Vega EA, Chun YS, David Tzeng C, Eng C, Vauthey JN, Conrad C. Minimally invasive management of the entire treatment sequence in patients with stage IV colorectal cancer: a propensity-score weighting analysis. HPB (Oxford). 2018 12; 20(12):1150-1156. PMID: 30005993.
      Citations: 1     Fields:    Translation:Humans
    74. Morris VK, Eng C. Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. J Natl Compr Canc Netw. 2018 07; 16(7):903-908. PMID: 30006430.
      Citations: 3     Fields:    Translation:HumansCells
    75. Osborne EM, Eng C, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Nancy You YQ, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das P. Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. Am J Clin Oncol. 2018 07; 41(7):632-637. PMID: 27755060.
      Citations: 5     Fields:    Translation:Humans
    76. Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 09; 100:35-45. PMID: 29936065.
      Citations: 11     Fields:    Translation:HumansCells
    77. Holliday EB, Lester SC, Harmsen WS, Eng C, Haddock MG, Krishnan S, Das P, Hallemeier CL. Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):102-108. PMID: 29907489.
      Citations: 3     Fields:    Translation:Humans
    78. Pande M, Joon A, Brewster AM, Chen WV, Hopper JL, Eng C, Shete S, Casey G, Schumacher F, Lin Y, Harrison TA, White E, Ahsan H, Andrulis IL, Whittemore AS, John EM, Ko Win A, Makalic E, Schmidt DF, Kapuscinski MK, Ochs-Balcom HM, Gallinger S, Jenkins MA, Newcomb PA, Lindor NM, Peters U, Amos CI, Lynch PM. Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. PLoS One. 2018; 13(4):e0196245. PMID: 29698419.
      Citations: 1     Fields:    Translation:Humans
    79. Hong DS, Moore K, Patel M, Grant SC, Burris HA, William WN, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell J. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 07 15; 24(14):3263-3272. PMID: 29643063.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    80. Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr BP, Miller E, Eng C, Simon GR, Ahmed S, Ferrajoli A, Romaguera J, Suarez-Almazor ME. Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. J Clin Oncol. 2018 Apr 01; 36(10):959-967. PMID: 29447061.
      Citations: 9     Fields:    
    81. Prinsloo S, Novy D, Driver L, Lyle R, Ramondetta L, Eng C, Lopez G, Li Y, Cohen L. The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial. J Pain Symptom Manage. 2018 05; 55(5):1276-1285. PMID: 29421164.
      Citations: 11     Fields:    Translation:Humans
    82. Ahmed S, Eng C. Role of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery. Curr Oncol Rep. 2018 01 23; 20(1):3. PMID: 29362905.
      Citations: 5     Fields:    Translation:Humans
    83. Johnson B, Eng C. The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. Clin Adv Hematol Oncol. 2017 Dec; 15(12):968-961. PMID: 29315288.
      Citations: 3     Fields:    Translation:Humans
    84. Holliday EB, Hunt A, You YN, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Bednarski BK, Eng C, Koay EJ, Minsky BD, Taniguchi C, Krishnan S, Herman JM, Das P. Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. J Gastrointest Oncol. 2017 Dec; 8(6):990-997. PMID: 29299359.
      Citations: 5     
    85. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072. PMID: 29180604.
      Citations: 80     Fields:    Translation:Humans
    86. Ahmed S, Eng C. Neoadjuvant Strategies: Locally Advanced Rectal Cancer. Clin Colon Rectal Surg. 2017 Nov; 30(5):383-386. PMID: 29184474.
      Citations: 5     
    87. Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzenburger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam F. Physician interpretation of genomic test results and treatment selection. Cancer. 2018 03 01; 124(5):966-972. PMID: 29165790.
      Citations: 4     Fields:    Translation:Humans
    88. Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, Eng C, Maru DM, Ychou M, Vauthey JN, Loyer EM, Kopetz S. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut. 2018 06; 67(6):1095-1102. PMID: 29084828.
      Citations: 8     Fields:    Translation:Humans
    89. Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188. PMID: 29051321.
      Citations: 63     Fields:    Translation:HumansCells
    90. Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol. 2017 Dec; 24(13):4051-4058. PMID: 28936799.
      Citations: 14     Fields:    Translation:Humans
    91. Rogers JE, Eng C. Pharmacotherapy of Anal Cancer. Drugs. 2017 Sep; 77(14):1519-1530. PMID: 28770514.
      Citations: 3     Fields:    Translation:Humans
    92. Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949. PMID: 28850629.
      Citations: 12     Fields:    Translation:Humans
    93. Sagebiel TL, Mohamed A, Matamoros A, Taggart MW, Doamekpor F, Raghav KP, Mann GN, Mansfield PF, Eng C, Royal RE, Foo WC, Ensor JE, Fournier KF, Overman MJ. Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. Ann Surg Oncol. 2017 Nov; 24(12):3667-3672. PMID: 28831698.
      Citations: 5     Fields:    Translation:Humans
    94. Morris V, Rao X, Pickering C, Foo WC, Rashid A, Eterovic K, Kim T, Chen K, Wang J, Shaw K, Eng C. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Mol Cancer Res. 2017 11; 15(11):1542-1550. PMID: 28784613.
      Citations: 22     Fields:    Translation:HumansAnimals
    95. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017 Oct 01; 35(28):3240-3261. PMID: 28759346.
      Citations: 159     Fields:    Translation:Humans
    96. Grotz TE, Overman MJ, Eng C, Raghav KP, Royal RE, Mansfield PF, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Ann Surg Oncol. 2017 Sep; 24(9):2646-2654. PMID: 28695394.
      Citations: 8     Fields:    Translation:Humans
    97. Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P, Kopetz S, Messick C, Skibber JM, Chang GJ. Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. J Clin Oncol. 2017 Aug 10; 35(23):2631-2638. PMID: 28657814.
      Citations: 23     Fields:    Translation:Humans
    98. Long Y, Sanchez-Espiridion B, Lin M, White L, Mishra L, Raju GS, Kopetz S, Eng C, Hildebrandt MAT, Chang DW, Ye Y, Liang D, Wu X. Global and targeted serum metabolic profiling of colorectal cancer progression. Cancer. 2017 Oct 15; 123(20):4066-4074. PMID: 28640361.
      Citations: 26     Fields:    Translation:Humans
    99. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279. PMID: 28424412.
      Citations: 32     Fields:    Translation:Humans
    100. Park IJ, You YN, Skibber JM, Rodriguez-Bigas MA, Das P, Eng C, Kopetz S, Wolff RA, Crane CH, Krishnan S, Minsky B, Hu CY, Nguyen S, Chang GJ. Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2017 Jun; 40(3):277-282. PMID: 27028350.
      Citations: 5     Fields:    Translation:Humans
    101. Hwang JP, Suarez-Almazor ME, Cantor SB, Barbo A, Lin HY, Ahmed S, Chavez-MacGregor M, Donato-Santana C, Eng C, Ferrajoli A, Fisch MJ, McLaughlin P, Simon GR, Rondon G, Shpall EJ, Lok AS. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer. 2017 Sep 01; 123(17):3367-3376. PMID: 28518219.
      Citations: 4     Fields:    Translation:HumansCells
    102. You YN, Shiozaki H, Lee JE, Passot G, Goumard C, Okuno M, Aloia TA, Eng C, Chang G, Vauthey JN, Conrad C. Total Laparoscopic Management for Stage IV Colorectal Cancer Requiring Multivisceral Resection. Ann Surg Oncol. 2017 Sep; 24(9):2595. PMID: 28510798.
      Citations:    Fields:    Translation:Humans
    103. Uemura M, Qiao W, Fournier K, Morris J, Mansfield P, Eng C, Royal RE, Wolff RA, Raghav K, Mann GN, Overman MJ. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer. 2017 05 15; 17(1):331. PMID: 28506255.
      Citations: 4     Fields:    Translation:Humans
    104. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8). PMID: 28422758.
      Citations: 13     Fields:    
    105. Gunther JR, Chadha AS, Shin US, Park IJ, Kattepogu KV, Grant JD, Weksberg DC, Eng C, Kopetz SE, Das P, Delclos ME, Kaur H, Maru DM, Skibber JM, Rodriguez-Bigas MA, You YN, Krishnan S, Chang GJ. Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):455-464. PMID: 29114614.
      Citations: 10     
    106. Sturgeon JD, Crane CH, Krishnan S, Minsky BD, Skibber JM, Rodriguez-Bigas MA, Chang GJ, You YN, Eng C, Das P. Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. Am J Clin Oncol. 2017 Apr; 40(2):163-166. PMID: 25222072.
      Citations: 7     Fields:    Translation:Humans
    107. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4146-4154. PMID: 28280091.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    108. Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One. 2017; 12(3):e0173345. PMID: 28267766.
      Citations: 40     Fields:    
    109. Zhao L, Chang DW, Gong Y, Eng C, Wu X. Measurement of DNA damage in peripheral blood by the ?-H2AX assay as predictor of colorectal cancer risk. DNA Repair (Amst). 2017 05; 53:24-30. PMID: 28291710.
      Citations: 5     Fields:    Translation:HumansCells
    110. Prinsloo S, Novy D, Driver L, Lyle R, Ramondetta L, Eng C, McQuade J, Lopez G, Cohen L. Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study. Cancer. 2017 06 01; 123(11):1989-1997. PMID: 28257146.
      Citations: 12     Fields:    Translation:Humans
    111. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 04; 18(4):446-453. PMID: 28223062.
      Citations: 120     Fields:    Translation:HumansCTClinical Trials
    112. Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Hung MC, Sood AK, Shureiqi I. Metastasis regulation by PPARD expression in cancer cells. JCI Insight. 2017 01 12; 2(1):e91419. PMID: 28097239.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    113. Tao R, Tsai CJ, Jensen G, Eng C, Kopetz S, Overman MJ, Skibber JM, Rodriguez-Bigas M, Chang GJ, You YN, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das P. Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol. 2017 01; 122(1):146-151. PMID: 28057329.
      Citations: 16     Fields:    Translation:Humans
    114. Morris V, Eng C. Metastatic Anal Cancer and Novel Agents. Surg Oncol Clin N Am. 2017 01; 26(1):133-142. PMID: 27889032.
      Citations: 2     Fields:    Translation:Humans
    115. Yamashita S, Loyer E, Kang HC, Aloia TA, Chun YS, Mehran RJ, Eng C, Lee JE, Vauthey JN, Conrad C. Total Transthoracic Approach Facilitates Laparoscopic Hepatic Resection in Patients with Significant Prior Abdominal Surgery. Ann Surg Oncol. 2017 May; 24(5):1376-1377. PMID: 27878479.
      Citations: 5     Fields:    Translation:Humans
    116. Liu C, Eng C, Shen J, Lu Y, Takata Y, Mehdizadeh A, Chang GJ, Rodriguez-Bigas MA, Li Y, Chang P, Mao Y, Hassan MM, Wang F, Li D. Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. Oncotarget. 2016 Nov 15; 7(46):76250-76260. PMID: 27788488.
      Citations: 42     Fields:    Translation:HumansCells
    117. Eng C. Preface. Surg Oncol Clin N Am. 2017 01; 26(1):xv-xvi. PMID: 27889042.
      Citations:    Fields:    Translation:Humans
    118. Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016 Oct 11; 7(41):67495-67506. PMID: 27542211.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    119. Morris V, Eng C. Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. J Gastrointest Oncol. 2016 Oct; 7(5):721-726. PMID: 27747086.
      Citations: 3     
    120. Fournier K, Rafeeq S, Taggart M, Kanaby P, Ning J, Chen HC, Overman M, Raghav K, Eng C, Mansfield P, Royal R. Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Ann Surg Oncol. 2017 Jan; 24(1):187-193. PMID: 27660258.
      Citations: 13     Fields:    Translation:Humans
    121. Rogers JE, Ohinata A, Silva NN, Mehdizadeh A, Eng C. Epidermal growth factor receptor inhibition in metastatic anal cancer. Anticancer Drugs. 2016 09; 27(8):804-8. PMID: 27272412.
      Citations: 9     Fields:    Translation:Humans
    122. Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631. PMID: 27421137.
      Citations: 23     Fields:    Translation:Humans
    123. Eng C. POLE mutations in colorectal cancer: a new biomarker? Lancet Gastroenterol Hepatol. 2016 11; 1(3):176-177. PMID: 28404085.
      Citations: 5     Fields:    Translation:Humans
    124. Bailey HH, Chuang LT, duPont NC, Eng C, Foxhall LE, Merrill JK, Wollins DS, Blanke CD. American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. J Clin Oncol. 2016 05 20; 34(15):1803-12. PMID: 27069078.
      Citations: 25     Fields:    Translation:HumansPHPublic Health
    125. Eng C, Bessudo A, Hart LL, Severtsev A, Gladkov O, Müller L, Kopp MV, Vladimirov V, Langdon R, Kotiv B, Barni S, Hsu C, Bolotin E, von Roemeling R, Schwartz B, Bendell JC. A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. Int J Cancer. 2016 Jul 01; 139(1):177-86. PMID: 26891420.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    126. Rogers JE, Dasari A, Eng C. The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. Oncologist. 2016 05; 21(5):563-70. PMID: 27000464.
      Citations: 11     Fields:    Translation:HumansAnimals
    127. Wang XS, Shi Q, Dougherty PM, Eng C, Mendoza TR, Williams LA, Fogelman DR, Cleeland CS. Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology. 2016; 90(3):127-35. PMID: 26882477.
      Citations: 11     Fields:    Translation:Humans
    128. Rogers JE, Silva NN, Eng C. Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. J Gastrointest Oncol. 2015 Oct; 6(5):E82-5. PMID: 26487956.
      Citations: 2     
    129. Morris VK, Rashid A, Rodriguez-Bigas M, Das P, Chang G, Ohinata A, Rogers J, Crane C, Wolff RA, Eng C. Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist. 2015 Nov; 20(11):1247-52. PMID: 26382740.
      Citations: 11     Fields:    Translation:HumansCells
    130. Eng C. Circulating DNA biomarkers: a primer for metastatic colorectal cancer? Lancet Oncol. 2015 Aug; 16(8):878-9. PMID: 26184521.
      Citations: 1     Fields:    Translation:Humans
    131. Dawood S, Sirohi B, Shrikhande SV, Toh HC, Eng C. Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study. Indian J Surg Oncol. 2015 Sep; 6(3):198-206. PMID: 27217664.
      Citations: 3     
    132. Kneuertz PJ, Chang GJ, Hu CY, Rodriguez-Bigas MA, Eng C, Vilar E, Skibber JM, Feig BW, Cormier JN, You YN. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 2015 May; 150(5):402-9. PMID: 25806815.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    133. Overman MJ, Eng C, Raghav K, Matamoros A, Taggart M, Foo WC, Fournier K. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist. 2015 Mar; 20(3):e3-4. PMID: 25745054.
      Citations: 2     Fields:    Translation:Humans
    134. Choe JH, Overman MJ, Fournier KF, Royal RE, Ohinata A, Rafeeq S, Beaty K, Phillips JK, Wolff RA, Mansfield PF, Eng C. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol. 2015 Aug; 22(8):2578-84. PMID: 25582740.
      Citations: 11     Fields:    Translation:Humans
    135. Eng C, Roach N, Longabaugh M, Fisher G. Perspectives on clinical trials for gastrointestinal malignancies. Am Soc Clin Oncol Educ Book. 2015; 40-3. PMID: 25993140.
      Citations:    Fields:    Translation:Humans
    136. Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2015 Feb; 51(3):271-81. PMID: 25542058.
      Citations: 40     Fields:    Translation:Humans
    137. Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015 Feb 03; 112(3):424-8. PMID: 25535726.
      Citations: 40     Fields:    Translation:Humans
    138. Rogers JE, Eng C. Cetuximab in refractory squamous cell carcinoma of the anal canal. J Gastrointest Cancer. 2014 Dec; 45 Suppl 1:198-200. PMID: 24908401.
      Citations: 4     Fields:    Translation:Humans
    139. Eng C, Chang GJ, You YN, Das P, Rodriguez-Bigas M, Xing Y, Vauthey JN, Rogers JE, Ohinata A, Pathak P, Sethi S, Phillips JK, Crane CH, Wolff RA. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014 Nov 30; 5(22):11133-42. PMID: 25373735.
      Citations: 34     Fields:    Translation:Humans
    140. Mitchell MP, Abboud M, Eng C, Beddar AS, Krishnan S, Delclos ME, Crane CH, Das P. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2014 Oct; 37(5):461-6. PMID: 23466576.
      Citations: 24     Fields:    Translation:Humans
    141. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014 Sep 20; 32(27):2975-84. PMID: 25002720.
      Citations: 53     Fields:    Translation:Humans
    142. de Carvalho Barbosa M, Kosturakis AK, Eng C, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Wang XS, Cleeland CS, Dougherty PM. A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. Cancer Res. 2014 Nov 01; 74(21):5955-62. PMID: 25183707.
      Citations: 26     Fields:    Translation:Humans
    143. Ahmed S, Eng C. Optimal treatment strategies for anal cancer. Curr Treat Options Oncol. 2014 Sep; 15(3):443-55. PMID: 25008956.
      Citations: 1     Fields:    Translation:Humans
    144. Subbiah IM, Blackmon SH, Correa AM, Kee B, Vaporciyan AA, Swisher SG, Eng C. Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. Oncotarget. 2014 Aug 30; 5(16):6584-93. PMID: 25051371.
      Citations: 7     Fields:    Translation:Humans
    145. Morris VK, Lucas FAS, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol. 2014 Oct; 25(10):2008-2014. PMID: 25009008.
      Citations: 29     Fields:    Translation:Humans
    146. Eng C, Ahmed S. Optimal management of squamous cell carcinoma of the anal canal: where are we now? Expert Rev Anticancer Ther. 2014 Aug; 14(8):877-86. PMID: 24981728.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    147. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71. PMID: 25069797.
      Citations: 48     Fields:    Translation:Humans
    148. Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, Davidenko I, Stephenson J, Elez E, Prenen H, Deng H, Tang R, McCaffery I, Oliner KS, Chen L, Gansert J, Loh E, Smethurst D, Tabernero J. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res. 2014 Aug 15; 20(16):4240-50. PMID: 24919569.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    149. Law L, Rogers J, Eng C. Delayed Presentation of DPD Deficiency in Colorectal Cancer. J Adv Pract Oncol. 2014 May; 5(3):205-10. PMID: 25089219.
      Citations: 1     
    150. Rogers JE, Crane CH, Das P, Delclos M, Gould MS, Ohinata A, Malatek D, Eng C. Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2014 Mar; 7(2):65-8. PMID: 24799976.
      Citations: 4     
    151. Haynes AB, You YN, Hu CY, Eng C, Kopetz ES, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Chang GJ. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer. 2014 Apr 15; 120(8):1162-70. PMID: 24474245.
      Citations: 15     Fields:    Translation:Humans
    152. Blackham AU, Swett K, Eng C, Sirintrapun J, Bergman S, Geisinger KR, Votanopoulos K, Stewart JH, Shen P, Levine EA. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2014 Jun; 109(7):740-5. PMID: 24375188.
      Citations: 17     Fields:    Translation:Humans
    153. Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch MJ. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2014 May; 22(5):1223-31. PMID: 24362907.
      Citations: 41     Fields:    Translation:Humans
    154. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):301-5. PMID: 24315563.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    155. Rogers JE, Ohinata A, Dasari A, Eng C. Atypical metastatic presentations in colorectal cancer: a case series. Clin Colorectal Cancer. 2014 Mar; 13(1):e1-4. PMID: 24342822.
      Citations: 3     Fields:    Translation:Humans
    156. Raghav KP, Shetty AV, Kazmi SM, Zhang N, Morris J, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013; 18(12):1270-7. PMID: 24149137.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    157. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013; 8(10):e77117. PMID: 24143206.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    158. Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, You YN, Das P, Krishnan S, Crane CH, Rodriguez-Bigas M, Skibber J, Ellis L, Eng C, Kopetz S, Maru DM. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013 Dec 15; 119(24):4231-41. PMID: 24089344.
      Citations: 21     Fields:    Translation:Humans
    159. Eng C, Chang GJ, You YN, Das P, Xing Y, Delclos M, Wolff RA, Rodriguez-Bigas MA, Skibber J, Ohinata A, Gould S, Phillips J, Crane CH. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013 Nov 01; 119(21):3769-75. PMID: 24037775.
      Citations: 12     Fields:    Translation:Humans
    160. Overman MJ, Fournier K, Hu CY, Eng C, Taggart M, Royal R, Mansfield P, Chang GJ. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg. 2013 Jun; 257(6):1072-8. PMID: 23001080.
      Citations: 24     Fields:    Translation:Humans
    161. Eng C. Will PICCOLO affect metastatic colorectal cancer therapy? Lancet Oncol. 2013 Jul; 14(8):679-80. PMID: 23725852.
      Citations:    Fields:    Translation:Humans
    162. Skinner HD, Crane CH, Garrett CR, Eng C, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Kelly P, Sandulache VC, Delclos ME, Krishnan S, Das P. Metformin use and improved response to therapy in rectal cancer. Cancer Med. 2013 Feb; 2(1):99-107. PMID: 24133632.
      Citations: 41     Fields:    Translation:Humans
    163. Liu SV, Lenkiewicz E, Evers L, Holley T, Kiefer J, Ruiz C, Glatz K, Bubendorf L, Demeure MJ, Eng C, Ramanathan RK, Von Hoff DD, Barrett MT. Genomic analysis and selected molecular pathways in rare cancers. Phys Biol. 2012 Dec; 9(6):065004. PMID: 23196986.
      Citations: 3     Fields:    Translation:Humans
    164. Bilen MA, Taggart MW, Fournier K, Ellis LM, Mansfield PF, Eng C, Royal RE, Overman MJ. Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series. Acta Oncol. 2013 Jun; 52(5):1044-6. PMID: 23020527.
      Citations: 1     Fields:    Translation:Humans
    165. Kim DD, Eng C. The promise of mTOR inhibitors in the treatment of colorectal cancer. Expert Opin Investig Drugs. 2012 Dec; 21(12):1775-88. PMID: 22978346.
      Citations: 15     Fields:    Translation:HumansAnimals
    166. Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, Ellis LM, Wu X. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer. 2012 Dec 15; 118(24):6188-98. PMID: 22673945.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    167. Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, Hawk ET, Wu X. Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res. 2012 Jul 15; 18(14):3982-91. PMID: 22661538.
      Citations: 35     Fields:    Translation:Humans
    168. Kim DD, Eng C. The current state of targeted agents in rectal cancer. Int J Surg Oncol. 2012; 2012:406830. PMID: 22675625.
      Citations: 4     Fields:    
    169. Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC. Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012 May; 8(5):623-33. PMID: 22512706.
      Citations: 39     Fields:    Translation:HumansCells
    170. Silva NN, Eng C. Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy. J Adv Pract Oncol. 2012 May; 3(3):161-9. PMID: 25031942.
      Citations: 2     
    171. Dai J, Gu J, Huang M, Eng C, Kopetz ES, Ellis LM, Hawk E, Wu X. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis. 2012 Jul; 33(7):1327-31. PMID: 22505654.
      Citations: 30     Fields:    Translation:Humans
    172. Boyette-Davis JA, Eng C, Wang XS, Cleeland CS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Zhang H, Dougherty PM. Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res. 2012 Jun 01; 18(11):3180-7. PMID: 22496202.
      Citations: 26     Fields:    Translation:Humans
    173. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJ. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012 May 20; 30(15):1770-6. PMID: 22493423.
      Citations: 183     Fields:    Translation:Humans
    174. Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, Eng C, Hassan MM. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer. 2012 Apr 10; 106(8):1374-8. PMID: 22421948.
      Citations: 68     Fields:    Translation:Humans
    175. Lin M, Eng C, Hawk ET, Huang M, Greisinger AJ, Gu J, Ellis LM, Wu X, Lin J. Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis. 2012 Apr; 33(4):841-7. PMID: 22318908.
      Citations: 3     Fields:    Translation:HumansCells
    176. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C. Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer. 2012 Sep; 11(3):191-4. PMID: 22280844.
      Citations: 7     Fields:    Translation:Humans
    177. Cheng L, Eng C, Nieman LZ, Kapadia AS, Du XL. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol. 2011 Dec; 34(6):573-80. PMID: 21217399.
      Citations: 72     Fields:    Translation:Humans
    178. Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, Sood AK. A novel platform for detection of CK+ and CK- CTCs. Cancer Discov. 2011 Dec; 1(7):580-6. PMID: 22180853.
      Citations: 86     Fields:    Translation:HumansCells
    179. Eng C. Carcinoma of the anal canal: small steps in treatment advances. Clin Adv Hematol Oncol. 2011 Sep; 9(9):662-9. PMID: 22402509.
      Citations:    Fields:    Translation:Humans
    180. Aklilu M, Eng C. The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol. 2011 Aug 09; 8(11):649-59. PMID: 21826084.
      Citations: 44     Fields:    Translation:Humans
    181. Tan CH, Bhosale PR, Das P, Crane CH, Viswanathan C, Raval B, Eng C, Iyer RB. Multidetector computed tomography follow-up of hypoattenuating small liver lesions in patients with rectal cancer. Am J Clin Oncol. 2011 Aug; 34(4):411-6. PMID: 20686401.
      Citations: 4     Fields:    Translation:Humans
    182. El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1646-51. PMID: 21748296.
      Citations: 66     Fields:    Translation:HumansCTClinical Trials
    183. Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJ. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012 Mar; 23(3):652-658. PMID: 21653683.
      Citations: 35     Fields:    Translation:Humans
    184. Garrett CR, Eng C. Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther. 2011 Jul; 11(7):937-49. PMID: 21557708.
      Citations: 20     Fields:    Translation:Humans
    185. Tanaka M, Chang P, Li Y, Li D, Overman M, Maru DM, Sethi S, Phillips J, Bland GL, Abbruzzese JL, Eng C. Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. Clin Cancer Res. 2011 Jul 01; 17(13):4531-40. PMID: 21551253.
      Citations: 22     Fields:    Translation:HumansCells
    186. Watkins J, Slade JH, Phan A, Eng C, Weissferdt A, Overman MJ. Fatal diffuse alveolar damage associated with oxaliplatin administration. Clin Colorectal Cancer. 2011 Sep; 10(3):198-202. PMID: 21855043.
      Citations: 6     Fields:    Translation:Humans
    187. Tsai CJ, Crane CH, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Feig BW, Eng C, Krishnan S, Maru DM, Das P. Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer. 2011 Aug 15; 117(16):3713-22. PMID: 21328329.
      Citations: 22     Fields:    Translation:Humans
    188. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011 Mar 10; 29(8):1083-90. PMID: 21263087.
      Citations: 119     Fields:    Translation:Humans
    189. Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer. 2010 Nov 15; 116(22):5325-35. PMID: 20665488.
      Citations: 34     Fields:    Translation:Humans
    190. Pande M, Amos CI, Eng C, Frazier ML. Interactions between cigarette smoking and selected polymorphisms in xenobiotic metabolizing enzymes in risk for colorectal cancer: A case-only analysis. Mol Carcinog. 2010 Nov; 49(11):974-80. PMID: 20886582.
      Citations: 7     Fields:    Translation:Humans
    191. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010 Sep 01; 116(17):4086-94. PMID: 20564148.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    192. Eng C. Are herbal medicines ripe for the cancer clinic? Sci Transl Med. 2010 Aug 18; 2(45):45ps41. PMID: 20720215.
      Citations: 6     Fields:    Translation:HumansAnimals
    193. Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJ. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol. 2010 Nov; 17(11):2863-9. PMID: 20552409.
      Citations: 41     Fields:    Translation:Humans
    194. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010 May 20; 28(15):2549-55. PMID: 20406923.
      Citations: 69     Fields:    Translation:Humans
    195. Wang XS, Williams LA, Eng C, Mendoza TR, Shah NA, Kirkendoll KJ, Shah PK, Trask PC, Palos GR, Cleeland CS. Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer. 2010 Apr 15; 116(8):2053-63. PMID: 20166216.
      Citations: 27     Fields:    Translation:Humans
    196. Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, Delclos ME, Krishnan S, Janjan NA, Crane CH. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer. 2010 Feb 15; 116(4):822-9. PMID: 20041481.
      Citations: 27     Fields:    Translation:HumansPHPublic Health
    197. Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, Ohinata A, Liu J, Wang X, Eng C. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010 Jan 15; 116(2):316-22. PMID: 19904805.
      Citations: 37     Fields:    Translation:Humans
    198. Eng C. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist. 2010; 15(1):73-84. PMID: 20067946.
      Citations: 12     Fields:    Translation:Humans
    199. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9. PMID: 20008624.
      Citations: 186     Fields:    Translation:HumansCTClinical Trials
    200. Chang GJ, Rodriguez-Bigas MA, Eng C, Skibber JM. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer. 2009 Dec 01; 115(23):5432-40. PMID: 19673001.
      Citations: 32     Fields:    Translation:Humans
    201. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, Schrag D, Seidenfeld J, Benson AB. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010 Jan 20; 28(3):493-508. PMID: 19841322.
      Citations: 138     Fields:    Translation:Humans
    202. Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MA. Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol. 2009 Dec 10; 27(35):5938-43. PMID: 19805670.
      Citations: 38     Fields:    Translation:Humans
    203. Eng C, Kopetz S. Commentary: practice patterns and potential impact on quality measures for a practicing physician. J Oncol Pract. 2009 Sep; 5(5):233-5. PMID: 20856734.
      Citations: 1     Fields:    
    204. Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Bedi M, Krishnan S, Crane CH. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):60-5. PMID: 19695792.
      Citations: 28     Fields:    Translation:HumansPHPublic Health
    205. Chang GJ, Gonzalez RJ, Skibber JM, Eng C, Das P, Rodriguez-Bigas MA. A twenty-year experience with adenocarcinoma of the anal canal. Dis Colon Rectum. 2009 Aug; 52(8):1375-80. PMID: 19617747.
      Citations: 14     Fields:    Translation:Humans
    206. Eng C, Pathak P. Treatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol. 2008 Dec; 9(4-6):400-7. PMID: 19479383.
      Citations: 5     Fields:    Translation:Humans
    207. Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, Wolff RA, Tortorice ML, Tansey P, Gonzalez-Moreno S, Lambert DH, Mansfield PF. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009 Aug; 16(8):2181-7. PMID: 19475451.
      Citations: 21     Fields:    Translation:Humans
    208. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 01; 27(22):3677-83. PMID: 19470929.
      Citations: 440     Fields:    Translation:Humans
    209. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):824-30. PMID: 19464823.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    210. Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci. 2010 Apr; 55(4):1098-105. PMID: 19399614.
      Citations: 20     Fields:    Translation:Humans
    211. Eng C. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol. 2009 Apr; 6(4):207-18. PMID: 19333227.
      Citations: 22     Fields:    Translation:Humans
    212. Hodges JC, Das P, Eng C, Reish AG, Beddar AS, Delclos ME, Krishnan S, Crane CH. Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. Int J Radiat Oncol Biol Phys. 2009 Nov 01; 75(3):791-4. PMID: 19231109.
      Citations: 7     Fields:    Translation:Humans
    213. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009 Jun 01; 27(16):2598-603. PMID: 19164203.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    214. Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das P. Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys. 2009 Jul 01; 74(3):818-23. PMID: 19147305.
      Citations: 19     Fields:    Translation:Humans
    215. Eng C, Crane CH, Rodriguez-Bigas MA. Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal? Nat Clin Pract Gastroenterol Hepatol. 2009 Jan; 6(1):16-7. PMID: 19047998.
      Citations: 1     Fields:    
    216. Fogelman DR, Kopetz S, Eng C. Emerging drugs for colorectal cancer. Expert Opin Emerg Drugs. 2008 Dec; 13(4):629-42. PMID: 19046131.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    217. Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51. PMID: 18936472.
      Citations: 175     Fields:    Translation:Humans
    218. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer. 2008 Sep; 7(5):338-42. PMID: 18794067.
      Citations:    Fields:    Translation:Humans
    219. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20; 26(12):2000-5. PMID: 18421052.
      Citations: 2     Fields:    Translation:Humans
    220. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 10; 26(14):2311-9. PMID: 18390971.
      Citations: 306     Fields:    Translation:HumansCTClinical Trials
    221. Eng C. K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2008 Mar; 6(3):174-5. PMID: 18391915.
      Citations: 2     Fields:    Translation:Humans
    222. Yu TK, Bhosale PR, Crane CH, Iyer RB, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Das P. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1175-80. PMID: 18207667.
      Citations: 20     Fields:    Translation:Humans
    223. Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer. 2008 Jan; 7(1):55-9. PMID: 18279578.
      Citations: 4     Fields:    Translation:Humans
    224. Das P, Crane CH, Eng C, Ajani JA. Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res. 2008 Jan; 2(1):10-4. PMID: 19259318.
      Citations: 16     
    225. Bhaskara A, Eng C. Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin Colorectal Cancer. 2008 Jan; 7(1):65-8. PMID: 18279580.
      Citations: 9     Fields:    Translation:Humans
    226. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, Chang DZ, Curley SA, Abdalla EK, Ellis LM, Vauthey JN. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007 Dec 15; 110(12):2761-7. PMID: 17960603.
      Citations: 118     Fields:    Translation:Humans
    227. Murthy R, Eng C, Krishnan S, Madoff DC, Habbu A, Canet S, Hicks ME. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol. 2007 Dec; 18(12):1588-91. PMID: 18057297.
      Citations: 9     Fields:    Translation:Humans
    228. Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008 Mar; 19(3):577-82. PMID: 18024857.
      Citations: 35     Fields:    Translation:Humans
    229. Eng C. Combining targeted therapies to enhance the effectiveness of chemotherapy in patients with treatment-refractory colorectal cancer. Clin Colorectal Cancer. 2007 Oct; 6 Suppl 2:S53-9. PMID: 18021488.
      Citations:    Fields:    Translation:HumansCells
    230. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg. 2007 Nov; 11(11):1498-504; discussion 1504-5. PMID: 17849166.
      Citations: 41     Fields:    Translation:Humans
    231. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007 May 01; 109(9):1750-5. PMID: 17387743.
      Citations: 124     Fields:    Translation:Humans
    232. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):794-800. PMID: 17379452.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    233. Bedi M, Das P, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Eng C, Wolff RA, Janjan NA, Krishnan S, Crane CH. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointest Cancer Res. 2007 Mar; 1(2):44-8. PMID: 19262718.
      Citations: 2     
    234. Swartz RJ, de Moor C, Cook KF, Fouladi RT, Basen-Engquist K, Eng C, Carmack Taylor CL. Mode effects in the center for epidemiologic studies depression (CES-D) scale: personal digital assistant vs. paper and pencil administration. Qual Life Res. 2007 Jun; 16(5):803-13. PMID: 17295102.
      Citations: 15     Fields:    Translation:Humans
    235. Malik Z, Eng C. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer. Clin Adv Hematol Oncol. 2007 Jan; 5(1 Suppl 1):4-7. PMID: 17491584.
      Citations:    Fields:    Translation:Humans
    236. Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris J, Vadhan-Raj S, Hamilton SR, Lin EH. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):762-71. PMID: 17011451.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    237. Das P, Lin EH, Bhatia S, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Delclos ME, Krishnan S, Janjan NA, Crane CH. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1378-83. PMID: 17056196.
      Citations: 25     Fields:    Translation:Humans
    238. Eng C. Anal cancer: current and future methodology. Cancer Invest. 2006 Aug-Sep; 24(5):535-44. PMID: 16939964.
      Citations: 17     Fields:    Translation:Humans
    239. Eng C, Shalan N. Biological agents versus chemotherapy in the treatment of colorectal cancer. Expert Opin Pharmacother. 2006 Jul; 7(10):1251-71. PMID: 16805714.
      Citations: 1     Fields:    Translation:Humans
    240. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Levy LB, Ellis LM, Crane CH. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol. 2006 Jun; 29(3):219-24. PMID: 16755173.
      Citations: 56     Fields:    Translation:Humans
    241. Hoff PM, Wolff RA, Xiong H, Jones D, Lin E, Eng C, Dutta A, Bogaard KR, Abbruzzese JL. Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. Cancer. 2006 May 15; 106(10):2241-6. PMID: 16598762.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    242. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006 May 01; 24(13):2065-72. PMID: 16648507.
      Citations: 373     Fields:    Translation:Humans
    243. Abdalla EK, Eng C, Madary A, Vauthey JN. Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver. Clin Colorectal Cancer. 2006 Mar; 5(6):436-9. PMID: 16635283.
      Citations: 1     Fields:    Translation:Humans
    244. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005 May; 241(5):715-22, discussion 722-4. PMID: 15849507.
      Citations: 369     Fields:    Translation:Humans
    245. Eng C, Ramanathan RK, Ramathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT, Mani S, Kindler HL. A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol. 2004 Dec; 27(6):565-9. PMID: 15577433.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    246. Bonnen M, Crane C, Vauthey JN, Skibber J, Delclos ME, Rodriguez-Bigas M, Hoff PM, Lin E, Eng C, Wong A, Janjan NA, Feig BW. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Nov 15; 60(4):1098-105. PMID: 15519780.
      Citations: 39     Fields:    Translation:Humans
    247. Eng C, Abbruzzese JL. The treatment of colorectal carcinoma: standard chemotherapy and beyond. Clin Adv Hematol Oncol. 2004 Sep; 2(9):592-8. PMID: 16163242.
      Citations:    Fields:    Translation:Humans
    248. Milano MT, Haraf DJ, Stenson KM, Witt ME, Eng C, Mittal BB, Argiris A, Pelzer H, Kozloff MF, Vokes EE. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004 Aug 01; 10(15):4922-32. PMID: 15297392.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    249. Eng C, Kindler HL, Nattam S, Ansari RH, Kasza K, Wade-Oliver K, Vokes EE. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol. 2004 Jun; 15(6):928-32. PMID: 15151950.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    250. Eng C, Abbruzzese J, Minsky BD. Chemotherapy and radiation of anal canal cancer: the first approach. Surg Oncol Clin N Am. 2004 Apr; 13(2):309-20, viii. PMID: 15137959.
      Citations: 3     Fields:    Translation:Humans
    251. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Annals of Oncology. 26:731-736.
    252. Impact of multimodal therapy in locally recurrent rectal cancer. British Journal of Surgery. 103:753-762.
    253. Transthoracic Port Placement Increases Safety of Total Laparoscopic Posterior Sectionectomy. Annals of Surgical Oncology. 1.
    254. Colon cancer. 77-84.
    255. American society of clinical oncology statement. Journal of Clinical Oncology. 34:1803-1812.
    256. Colorectal cancer survivorship management. 71-93.
    257. Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials.
    258. Metastatic Anal Cancer and Novel Agents. Surgical Oncology Clinics of North America. 26:133-142.
    259. Epidermal growth factor receptor inhibition in metastatic anal cancer. Anti-Cancer Drugs. 27:804-808.
    260. Hyperfractionated accelerated reirradiation for rectal cancer. Radiotherapy and Oncology.
    261. Preface. Surgical Oncology Clinics of North America.
    262. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Investigational New Drugs.
    263. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer. BMC Cancer. 15.
    264. Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. Gastrointestinal Cancer Research. 7:65-68.
    265. MET amplification in metastatic colorectal cancer. Oncotarget. 7:54627-54631.
    266. Long-Term results of weekly/daily cisplatin-Based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Diseases of the Colon and Rectum. 57.
    267. Multidisciplinary management of stage IV colon cancer. Seminars in Colon and Rectal Surgery.
    268. Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. Journal of Gastrointestinal Oncology. 6:E82-E85.
    269. Clinical implications of circulating tumor cells in advanced colorectal cancer. Current Colorectal Cancer Reports. 8:233-242.
    270. Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. American Journal of Clinical Oncology: Cancer Clinical Trials.
    271. Pathologic complete response in poorly differentiated adenocarcinomas of the appendix. Acta Oncologica. 52:1046-1048.
    272. Cancer of the anal region.
    273. Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer. Indian Journal of Surgical Oncology. 6:198-206.
    274. The treatment of colorectal cancer during pregnancy. Oncologist. 21:563-570.
    275. Erratum. American Journal of Clinical Oncology: Cancer Clinical Trials. 28:455.
    276. Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. Oncotarget. 7:76250-76260.
    277. POLE mutations in colorectal cancer. The Lancet Gastroenterology and Hepatology. 1:176-177.
    278. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer. Oncotarget. 7:67495-67506.
    279. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Annals of Oncology. 27:1068-1074.
    280. Colon, rectal, and anal cancer management. 711-739.
    281. Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology (Switzerland).
    282. Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. American Journal of Clinical Oncology: Cancer Clinical Trials.
    283. Total Transthoracic Approach Facilitates Laparoscopic Hepatic Resection in Patients with Significant Prior Abdominal Surgery. Annals of Surgical Oncology. 1-2.
    284. Current and emerging trends in the treatment of metastatic colorectal cancer. Hematology/Oncology Clinics of North America. 21:8-17.
    285. Colorectal Cancer. 86-136.
    286. Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP). Annals of Surgical Oncology. 1-7.
    287. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer outcomes and toxicity. American Journal of Clinical Oncology: Cancer Clinical Trials. 37:461-466.
    288. Building on the foundation of 5-FU to treat metastatic colorectal cancer. Oncology. 22:462-468.
    ENG's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (560)
    Explore
    _
    Co-Authors (177)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _